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In this issue of Immunity, a collection of detailed reviews summarizes needs, opportunities, and roadblocks
to the development of new vaccines, all in the context of our current knowledge and understanding of
key aspects of immune function and microbial interactions with the host. This Perspective is designed to
provide a broad overview that discusses our present limitations in designing effective novel vaccines for
diseases that do not typically induce robust resistance in infected individuals and how the addition of
a systems-level, multiplexed approach to the analysis of the human immune system can complement tradi-
tional highly focused research efforts to accelerate our progress toward this goal and the improvement of
human health.Introduction
Life is a constant battle to survive and reproduce in a particular
ecological niche, in competition with other organisms that seek
to occupy and thrive in the same environment. In many cases,
such competition is not between free-dwelling species indepen-
dently seeking adequate resources, but between predator and
prey. For humans in particular, if we exclude intraspecies con-
flicts (would that this was the case in reality!), the real battle is
between us as prey and the microbial and/or parasitic world as
predators. Beyond the physical barriers of skin and mucous
membranes, our ability to prevail in this battle is dependent on
the proper functioning of our immune system.
In this special issue of Immunity, experts in many of the
aspects of immune system organization and function relevant
to achieving immune resistance to infection, as well as others
with a deep knowledge of vaccinology, provide timely reviews
of the state of knowledge in their respective fields (Palucka
et al., 2010; Chen and Cerutti, 2010; Coffman et al., 2010;
Good and Doolan, 2010; Kaufmann, 2010; Liu, 2010; McElrath
and Haynes, 2010; Pulendran et al., 2010; Sette and Rappuoli,
2010). The information conveyed in these reviews is indeed
impressive. Yet, at the same time, they are revealing in what
they say about the limitations we still possess with respect to
understanding the true correlates of immunity for infections
involving HIV, Mycobacterium. tuberculosis, or Plasmodium.
falciparum and about our capacity for rational development of
effective vaccines against the wide range of organisms that still
cause substantial morbidity and mortality around the globe.
In this perspective, I present a less detailed, more descriptive
and prescriptive view of where we are now in understanding
human immune function and where we as a community need
to go to more effectively harness the immune system for
improved human health.
The Past Is Prologue
The existence of acquired or active immunity was implicit in
observations made long ago in human history, when it was
recognized that individuals who survived an overt infection
were most frequently resistant to that same disease in the future(Silverstein, 1999). However, the practical utility of this knowl-
edge was not fully appreciated until Edward Jenner (and others
who have received less attention) undertook the use of a less
pathogenic form of a virulent organism to actively protect against
infection. The science (or art) of vaccinology is indeed frequently
considered to have begun with Jenner’s use of cowpox as
a vaccine against smallpox, based on his observation that milk-
maids who suffered the former infection were typically resistant
to the latter (Gross and Sepkowitz, 1998; Kennedy et al., 2009;
Plotkin, 2009). Rather than rely on survival of natural infection,
the paradigm was established that medical intervention could
precipitate an immune (pathogen-resistant) state with minimal
risk to the individual through administration of a (relatively) non-
toxic or nonpathogenic counterpart of the agent or organism
against which resistance was desired.
From this modest beginning in the 18th century, the practice of
vaccinology has undergone tremendous development. Initially
through largely empirical routes involving isolation and inactiva-
tion of the toxic products of some microorganisms (tetanus
toxoid for example), the use of attenuated viruses (in the case
of polio or smallpox), or the use of killed versions of various path-
ogens (for example, influenza), we have developed and put to
use a large armamentarium of vaccines against bacterial and
viral diseases (reviewed in Plotkin, 2009; Pulendran et al.,
2010; Sette and Rappuoli, 2010). In conjunction with better sani-
tation, these vaccines have been responsible for a remarkable
reduction in early mortality from infectious diseases —indeed,
over just a few generations, the developed world has gone
from having the death of a child due to infection be a common-
place event to a rarity. Smallpox has been eliminated as
a disease and only small pockets of polio remain as a result of
intensive worldwide vaccination drives (Henderson, 1999).
Until the past few decades, successful vaccines were almost
exclusively against pathogens to which primary exposure
induced long-lasting resistance in the surviving host. That is,
we simply mimicked nature and induced the immune system
to respond in a manner that observations of the natural history
of disease showed were adequate to produce microbial resis-
tance. More recently, the development of glyco-conjugateImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 441
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organisms that typically colonize many of us on an ongoing
basis and cause invasive disease in a fraction of the population,
a prime example being Haemophilus influenza (Chandran et al.,
2005; Rappuoli, 2001; Sette and Rappuoli, 2010). In other cases,
prevaccination can prevent infection by agents that once
present in the body are not usually eradicated by the immune
system. For example, persistent infection and the promotion of
cancer by certain papilloma viruses can now be prevented by
using a virus-like particle protein-based vaccine (Gillison et al.,
2008; Trimble and Frazer, 2009; zur Hausen, 2009).
These achievements, especially those in which immunity has
been induced that is superior to that normally existing in the
host population, led in recent years to the hope—indeed in
some quarters the expectation—that academic and industrial
scientists could and would rapidly generate effective vaccines
to the many pathogens that remain major health issues. But
these expectations were not based on a deep understanding
of the history of vaccinology or the limits of our current under-
standing of both human immunity and its capacity to handle
some types of infectious agents. The reality is that nearly all
useful vaccines developed to date act through the production
of antibodies, neutralizing in the case of viruses or toxins or
opsonizing in the case of bacteria (see Ravanfar et al., 2009,
as well as Pulendran et al., 2010 and Sette and Rappuoli,
2010). These vaccines are rather specific, and for pathogens
with significant genetic diversity, our success has been limited
mainly to those cases in which the most highly pathogenic
strains of a virus or bacteria can be identified and in which these
limited numbers of serotypes do not vary substantially over time.
This permits multivalent vaccines to be devised that cover (most
of) the spectrum of strains to which resistance is desired—this is
the case for polio, pneumococcal vaccines, and many others.
Influenza, which does show significant variation in neutralizing
determinants over short time frames, is dealt with successfully
by vaccination because we have developed an early warning
system that allows seasonal manufacture of the specific vaccine
needed for that year, and indeed, protection can be limited if
there are multiple circulating strains in a given season (Fiore
et al., 2009).
We have learned over many years what the relevant surrogate
markers are for such antibody-mediated protection to geneti-
cally stable (or at least easily tracked) pathogens (Pulendran
et al., 2010). A large body of data has illuminated the relationship
between serum titers of antibodies of suitable specificity and
affinity to useful host protection, even when that protection is
mediated by these antibodies not in the bloodstream where
they are measured, but at sites of pathogen invasion such as
mucosal surfaces. For example, in classic studies of resistance
to respiratory syncitial virus (RSV), Chanock and colleagues
determined the amount of IgG in the serum that would lead to
transudation of an amount of this antibody that was effective at
neutralizing RSV on the lung epithelial surface and showed that
achieving that level of serum IgG through passive transfer
provided the expected protection against this virus (Prince
et al., 1985a; Prince et al., 1985b; Prince et al., 1985c). Although
for RSV, this insight has not led to a practical active vaccine for
various reasons, it has allowed effective passive therapy and
represents a highly useful method for evaluating pilot studies442 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.for the likely efficacy of other antibody-based vaccines before
they are put through expensive and time-consuming phase III
efficacy studies. It also can be used for postlicensing assess-
ment of whether individuals are likely to be protected or not,
based on minimal titers in the serum. A similar quantitative
approach relating serum IgG antibody concentration to effective
protection is commonly employed to determine whether or when
boosting is needed for a host of widely used vaccines.
However, this quantitative antibody paradigm is problematic
for diseases in which we do not know how much of what speci-
ficity of antibody of what isotype in what tissue site leads to
protection, or even knowing this, how to generate such anti-
bodies in adequate titer and to maintain such levels over many
years. It is also an issue when the pathogen varies in the relevant
target structures for such antibodies to such an extent that even
a multivalent vaccine would not generate adequate coverage of
the variants, or in cases in which the best neutralizing sites are
shielded by protein folds or carbohydrates, all of which are the
situation with HIV (Forsell et al., 2009; Kwong and Wilson,
2009; Schief et al., 2009).
But beyond this, there are many cases in which the humoral
antibody response does not seem to be the effector arm of the
immune system best able to protect against or eliminate partic-
ular pathogens, requiring us to develop an entirely new under-
standing of the relationship between cellular immunity and host
protection akin to that which decades of work have yielded for
antibody-based immunity. This is the case for mycobacteria,
for some viruses, and most likely, for many parasites. The chal-
lenge is all the greater because many of these same pathogens
are the very ones that do not typically produced robust resis-
tance upon initial infection, limiting our ability to count on the
natural response to guide us in how tomake a protective vaccine
or even to know if the immune system is capable of mediating
such resistance under optimal conditions.
A simple example in this area of limited knowledge of what to
aim for with a vaccine based on cell-mediated immunity is pro-
vided by considering the CD8+ cytotoxic T cell response, fre-
quently targeted as a primary effector modality in HIV vaccines
(Letvin, 2005). What state of differentiation of the mature effector
cells is required for their optimal activity—is it the content of per-
forin or granzymes (Migueles et al., 2008), the ability to make
cytokines or chemokines (Levy, 2003), or some other property
or combination of properties that is most important? What state
of differentiation at the time of infection (central memory, effector
memory, and active effectors) is best for providing protection
(Ahmed and Gray, 1996; Ehl et al., 1997) and how do we ensure
that a vaccine induces enough specific cells in the correct condi-
tion? If memory cells are most important, how do we deliver
a vaccine that favors their development over an acute effector
response—if active effectors must be present at the time of
infection, how dowe provide the antigenic stimulation necessary
to maintain these cells over long time intervals after vaccination
without risk of depletion (Moskophidis et al., 1993), desensitiza-
tion (Barber et al., 2006), or unacceptable levels of chronic tissue
inflammation? How many of the proper type of cell are needed
and how do we relate the number of antigen-specific cells
measured in the peripheral blood to what is in either secondary
lymphoid tissue or peripheral sites where these cells must
perform as precursors or differentiated effectors, respectively
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patterns are necessary to ensure proper homing of the ultimate
effector cells to the tissue sites where their action is most rele-
vant? Without such information, we are left with merely mea-
suring what we can (and not necessarily what we should) after
trying vaccine formulations whose design is not based on any
deep insight into what the vaccine must yield to be effective
and with only large and expensive field trials able to provide
any hints on whether we are moving in the right direction.
These various complexities all funnel into amajor bottleneck—
our limited understanding of the human immune system and,
hence, our capacity to optimally assess the state of the system
and to manipulate it in predictable ways. As recounted in the
reviews accompanying this perspective, we have a great deal
of information at present about the nature of antigen presenta-
tion and regulation of T and B cell differentiation by various
subsets of dendritic cells (Palucka et al., 2010); about the special
nature of the mucosal immune system (Chen and Cerutti, 2010);
the effects of diverse adjuvants on immune responses (Coffman
et al., 2010); the mechanisms used by pathogens such as HIV
(McElrath and Haynes, 2010), M. tuberculosis (Kaufmann,
2010), or P. falciparum (Good and Doolan, 2010) to evade
immune control and how these limitations might be overcome
by vaccination; the ability of viral and other vector platforms to
help promote effective responses (Liu, 2010); and the utility of
reverse vaccinology for identifying novel potential vaccine
components (Sette and Rappuoli, 2010). Yet even with all this
knowledge, there is a level of integrated understanding that is
clearly still lacking. What signals best promote persistent high-
titered antibody responses through production of long-lived
plasma cells derived from activated B cells with the right speci-
ficity of isotype-switched, somatically mutated immunoglobulin
loci? What are the antigen structures and form(s) of delivery
that will focus the specificity of such antibody responses on rele-
vant rather than distracting determinants of pathogen mole-
cules? Which T cell subset in what differentiated state and in
what numbers would be effective in protecting against those
agents for which antibodies are not the most effective mode of
resistance? In some cases, we know what response we need
but not how to get it— in others we are still ignorant of even
the right type of response or whether we have knowledge of
the full range of effector modalities that can be drawn on for
host defense, and hence, the best combination of responses
to promote to achieve effective immunity after vaccination.
Without such insight, it is exceedingly difficult to produce new
generations of vaccines that are likely to be effective and safe
against diseases in which natural resistance is not the norm.
If we are to move past these limitations and probe the limits of
human immunity as ameans of protection against a diverse array
of pathogens, it is apparent that a concerted effort to better
understand the operation of this system is required through
a combination of continued detailed analysis and a new
emphasis on systems level study, as so cogently discussed by
Pulendran et al. (2010). We must add to the existing research
portfolio of sharply focused studies of a small number of samples
from only a few individuals more robust, highly multiplexed, in-
depth analyses on larger populations and apply to these more
complete data sets new computational and statistical tools for
extracting biological insight. Fortunately, this need has beenrecognized and investigators and funding agencies are mobi-
lizing in a major effort to make rapid progress in this arena, in
large measure as an integrated community rather than as
competitive independent investigators. The remainder of this
perspective will discuss these emerging efforts, what they can
contribute to our rapid acquisition of a better grasp of human
immune function in health and disease, how the information
from such investigations can be put to use in vaccine research,
and some of the limitations of this new research direction.
Existing Paradigms and Accomplishments in Human
Immunological Research
The statement above about our lack of adequate understanding
of human immunity is not meant to imply that we do not know
a great deal or that the many investigators who have worked in
this arena have not made major strides forward in cataloging
the cellular and molecular components of the human immune
system, in dissecting how these elements interact to produce
function, or in characterizing what aspects of the system show
too little or too much activity in immunodeficiency or autoim-
mune states, respectively. Indeed, monoclonal antibodies were
first produced against and used to phenotype human hemato-
poietic cells (Reinherz and Schlossman, 1980, 1982), much of
the available data on signaling by the TCR was developed with
human T cell tumor cells (Imboden et al., 1985; Weiss et al.,
1984; Weiss et al., 1991), the initial cloning of cDNAs corre-
sponding many of the surface proteins identified by the anti-
lymphocyte and myeloid cell monoclonal antibodies that led to
the CD nomenclature involved human molecules (Aruffo and
Seed, 1987; Seed and Aruffo, 1987), and the relevance of
many of the components identified in these studies to host
defense is only really known fromexperiments of nature involving
genetic lesions in the human population.
A variety of distinct methods have generated our existing body
of knowledge of human immunity. Scientists and physicians in
the 19th and early 20th century made the first major contributions
to the field as a consequence of both natural history studies in
individuals with various diseases and laboratory analysis of
serum and tissues from infected or ill subjects. The work of Pas-
teur, von Pirquet, Schick, Portier and Richet, Bordet, Arthus, von
Behring, Kitasato, and many others provided an initial picture of
human immunity, including the antibody response to infection or
vaccination, the effector activities of antibodies in vitro and
in vivo, the nature of allergic and immunopathologic states,
and the existence of responses characterized by mononuclear
cell infiltrates, such as upon skin challenge of infected individuals
with extracts of mycobacteria, along with the systematic
capacity to provide protection of the host by passive and active
immunotherapy methods (Silverstein, 1999).
However, in the late 20th century, much of the focus in immu-
nological research shifted from humans to inbred mouse
models. The distinction between T and B lymphocyte subpopu-
lations of the small lymphocytes described by Gowans and their
need for cooperation in antibody responses was made in mouse
models (Miller, 1972), as were other major conceptual advances
such as MHC restriction (Zinkernagel and Doherty, 1974) and
thymic selection (Bevan and Fink, 1978; Zinkernagel, 1978).
Important novel subsets of hematopoietic cells such as dendritic
cells (Steinman and Cohn, 1973), NK T cells (reviewed inImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 443
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et al., 2003; Hori et al., 2003) were first discovered and charac-
terized in mouse models.
Human immune analysis moved along two paths during this
time period. One especially productive direction was the analysis
of the effects of genetic variation on response, in particular with
respect to susceptibility to specific infectious diseases in the
context of immunodeficiency. As more and more powerful tools
became available to identify the genetic locus responsible for an
immunodeficiency leading to the excess occurrence of specific
infections, such studies have provided remarkable insight into
which molecular players contribute to human host defense.
The advances arising from such studies have been elegantly
summarized in recent reviews (Alcaı¨s et al., 2009; Bustamante
et al., 2008; Casanova et al., 2008), so I will only mention that
the results range from the expected (IL-12-IL-12R interactions
are critical formycobacterial defense [Al-Muhsen andCasanova,
2008]) to the unexpected (the absence of the kinase IRAK-4,
considered critical in Toll-like receptor signaling, has a minimal
impact and only leads to enhanced susceptibility to a subset of
pyogenic infections [Picard et al., 2007]). Other patient-based
research has helped provide novel insights into apoptotic path-
ways (Chun and Lenardo, 2001) and the components of the
signal transduction machinery downstream of the TCR (Su
et al., 2005) or involved in CD4+ effector T cell polarization (Milner
et al., 2008).
Another path was the adoption of the ‘‘96-well plate’’ method
to probe the cellular and molecular aspects of immune function.
This method uses human cells in plastic and combines antibody
and drug treatments in such in vitro cultures with functional read
outs like proliferation or cytokine production along with dense
cell phenotyping using flow cytometry. Several laboratories
have been especially productive in using such methods and
have advanced the field by first identifying and classifying
subpopulations of memory T cells (Sallusto et al., 1999), work
that was later replicated in the mouse (reviewed in Seder and
Ahmed, 2003), by discerning specific phenotypic makers on
subsets of effector T cells that closely correlate with polarization
for cytokine production (Sallusto et al., 2000) or by relating
memory B cell status to both specific and unspecific effects of
vaccination on antibody titers (Bernasconi et al., 2002). Others
have used molecular methods to examine the precursor and
mature B cell repertoire for the existence of autoreactive B cell
receptors on human cells and the impact of genetic variations
that predispose to autoimmunity on the extent of repertoire trim-
ming affecting such specificities (Tiller et al., 2007; Wardemann
and Nussenzweig, 2007).
These few examples (highly selected from among a wealth of
critical discoveries made by many investigators) make apparent
the impact that even the ethically constrained studies that can be
performed on humans or with human cells has had not only on
our specific knowledge of the human immune system itself,
but more broadly with respect to vertebrate immunity. Yet
such efforts have not brought us to where we need to be to
design effective vaccines, especially those requiring a response
not readily engendered by natural infection. We have had only
limited recent success with developing a vaccine for blood-
stage malaria (Good and Doolan, 2010); BCG, despite its wide
spread use, is not highly effective in preventing M. tuberculosis444 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.infection and reactivation disease (Liu, 2010; Kaufmann, 2010);
for HIV, there is just a glimmer of success in the recent prime-
boost Thai trial and the mechanism(s) of the modest effect
seen is (are) not characterized (Rerks-Ngarm et al., 2009); we
lack protective vaccines for a wide array of helminth infections,
as well as for merging and re-emerging viral infections; and
some vaccines candidates against several agents produce
excess morbidity rather than protection, especially if infection
occurs with a strain of the pathogen that differs from that used
in the vaccine preparation (for example, with dengue [Webster
et al., 2009]).
Moving to the Future in Human Immunology
What are the limitations that are impeding progress? Various
opinions on this topic have been offered, many recently focusing
on the pervasive use of mouse models for the study of the
immune system (Davis, 2008). In truth, inbred mice have per-
formed admirably as an experimental model system for immuno-
logical investigation. The knowledge gained ranges across
multiple biological scales, from details of molecular architecture
to recent visualizations of dynamic cell behavior in living animals
to whole organism responses to infection or vaccination. But to
quote Hamlet—‘‘Ay, there’s the rub.’’ Despite this wealth of
immunological information, there is a growing realization that
all this knowledge derived frommouse studies has not produced
a proportional increase in our ability to understand and effec-
tively treat human diseases with an immunological basis or to
develop vaccine formulations that produce the right response
in adequate magnitude. To be clear —there are many examples
one can point to wheremouse-derived information has proven to
be important in better understanding the human condition and
has even guided development of therapeutic approaches. But
the translation of mouse findings to humans nevertheless is
much less robust than one would like, raising two major ques-
tions: why is this and how can the problem be addressed?
On the first issue, there are two major viewpoints, nicely
summarized in Davis’s recent piece in this journal (Davis,
2008). One holds that the mouse cannot be considered a ‘‘small
human,’’ that evolution has produced an organism suited to its
ecological niche that has a distinct physiology from that of hu-
mans and it is simply not possible with any great assurance to
extrapolate from one species to another. The clear documenta-
tion of molecular differences in key components of host defense
(Mestas and Hughes, 2004) (for example, themolecular nature of
innate NK cell inhibitory receptors) or in the cellular distribution of
orthologous gene products (for example, of TLR9) makes evi-
dent that there is at least some merit to this line of thinking.
The other view is that the way the mouse immune system is
typically challenged, manipulated, or studied experimentally is
so far afield from the conditions applicable to humans that the
information obtained in mice has much less relevance than it
could if the analyses had been done with more thought to their
suitability for cross-species comparisons. For example, the
route of antigen administration is typically subcutaneous or intra-
peritoneal in mice and intramuscular in humans; amounts of
antigen and adjuvant are not adjusted on a weight or body
surface basis and so on. In infectious disease models, the path-
ogen inoculum is often more than an order of magnitude higher
than what is involved in a natural infection. In studies of
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nization schedule is selected to obtain as close as possible to
100% penetrance of the disease, unlike many human clinical
situations. There is no question that all these issues contribute
to limiting effective translation of mouse results to the human
situation and that better design of animal studies aimed at
improving our understanding of human immunity would be
a good thing.
But whatever the proportional contribution of these or other
considerations to the difficulty of using mouse-derived informa-
tion to inform our view of human immunology, the answer to
the second question, ‘‘What can we do about the problem?,’’
has to be ‘‘Learn how to better study and analyze the immune
system of humans directly.’’ Many in the field who have been
‘‘mouse immunologists’’ for years now agree with the viewpoint
espoused in the call to arms by Davis for a much stronger, coor-
dinated, and extensive effort to probe, quantitatively measure,
and eventually manipulate human immune responses. But doing
so is not a simple task for a multitude of reasons.
One major issue is that the analysis of the human immune
system has largely been pursued piecemeal to date (one
disease, one gene, or one gene product) and usually on a
small scale. This is in part due to (1) the siloed nature of medi-
cal subspecialties that claim specific immunological diseases
as their own based largely on organ system and not the
underlying immune dysfunction at a cell or molecular level
and (2) the dominance of the reductionist approach that has
dominated biological inquiry both in experimental animals and
in humans for decades. The upshot of this balkanization and
microanalysis of human immunology is that our ability to
ameliorate and/or cure many serious human autoimmune dis-
eases remains limited, our insight into the likely shared patho-
physiological basis of diseases with inflammation as a common
denominator (arteriosclerotic cardiovascular disease, neurode-
generation, etc.) is restricted, and methods to manipulate the
immune system to treat autoimmune diseases, fight malignan-
cies, or, most relevant with respect to the present discussion,
develop vaccines by rational means are still at an early stage
of development.
A second problem is that even the best work is often done
separately by many distinct laboratories using different proto-
cols for nearly all of the tests, cell isolations, phenotyping, and
functional measurements, making it extraordinarily difficult to
compare data between studies and rendering optimal meta-
analysis problematic. This is related to the third limitation,
namely the small scale of many of the studies (a few or few dozen
patients), sampled at limited times and analyzed with a modest
number of tools of limited power. Unlike inbred or genetically
modifiedmice, humans are individuals not only with a highly vari-
able genotype but also with individual genetic imprinting, distinct
commensal flora, and variable exposure to disease-modifying
environmental factors, including divergent life styles. For these
reasons, and because of the strong influence of environment
and developmental history on immune function, analyses of
modest scope impede our ability to draw broadly applicable,
statistically reliable conclusions about the basis of disease or
even normal human immune function other than in those rare
cases of highly penetrant single-gene lesions causing immuno-
deficiency.On the opposite end of the spectrum are the large clinical
studies with thousands of patients conducted primarily to
analyze the effect of drug treatments on various immune-related
disease states or the efficacy of experimental vaccines. Some
hints about the functioning of the human innate or adaptive
immune system have come from these trials, but deep insight
has been limited in part because only a small number of samples
are collected and these are subjected to only a few assays. On
the other hand, the sequencing of the human genome (Lander
et al., 2001; Venter et al., 2001), the Hap-Map effort (http://
hapmap.ncbi.nlm.nih.gov/), and the development of SNP arrays
(Ragoussis, 2009) have together permitted genome-wide asso-
ciation studies in many immunological diseases (Lettre and
Rioux, 2008). The information provided by many of these studies
is robust and is slowly shedding light on the molecular and
genetic pathway underlying physiologic and pathologic immune
functions. However, because the effect of each individual poly-
morphism, mutation, or epigenetic variation is typically modest,
the scientific community at large has been slow to undertake
extensive tests of the physiologic significance as well as the
mechanistic aspects of many of associations suggested by
such studies.
Merely listing limitations with the field as it exists has less value
than suggesting how to overcome these impediments. Fortu-
nately, a convergence of technical developments and ‘‘Aha!’’
moments has begun to offer a new path forward toward this
goal that builds on the important but still limited insights noted
above. An increasing number of organizations and academic
centers, including but not limited to the NIH extramural program
(through such funding mechanisms as the Cooperative Centers
for Translational Research and Biodefense (http://www.cctrhib.
org/Other_CCTRHIBs.htm) and human immune profiling centers
(http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-09-040.html;
Pulendran et al., 2010), individual academic centers (for example,
Stanford’s new Institute for Immunity, Transplantation and Infec-
tion [http://iti.stanford.edu/] or Emory’s Vaccine Center [http://
www.vaccines.emory.edu/index.php]), the NIH Intramural Program
(http://www.nhlbi.nih.gov/resources/chi/index.htm), and a major
effort at King’s College in the UK (http://www.guysandstthomas.
nhs.uk/news/newsarchive/newsarticles/20100331hird-study.aspx),
have all recognized the need for large-scale, highly integrated, tech-
nologically driven programs to probe and measure human immune
responses in normal individuals, those whose immune systems are
intentionally perturbed in an ethical manner (most often through
administration of a vaccine), and in individuals with immune-based
diseases prior to and after therapeutic intervention (see Box 1).
At NIH, in response to this recognition, leaders frommany institutes
and the office of the director acted in concert with intramural
investigators to develop a trans-NIH research program, the Center
for Human Immunology, Autoimmunity and Inflammation (CHI),
which is designed to bridge the chasm between the rich world of
basic immunology research at the NIH and the in-depth study of
human immune diseases and inflammatory processes. The NIH
program takes advantage of the enormous expert community in
the intramural program whose members are involved in the study
of basic immunology using the mouse model and also the many
physician-scientists who have been pioneers in the direct investiga-
tionandclinicalmanipulationof thehuman immunesystem.TheCHI
will also have the unique advantage of the Clinical Research CenterImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 445
Box 1. Selected Resources for the Global Study of Human Immunity
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investigators with an ability to do clinical studies expeditiously and
with fewer constraints than in typical academic hospitals. Academic
centerswithsimilarly richgroupingsofbasicandclinical immunology
investigators are also banding together internally to pursue similar
large-scale analyses of humans and human material, as detailed in
the accompanying review on systems immunology (Pulendran
et al., 2010).
A superb basic and clinical research infrastructure and
a substantial cohort of expert investigators are not enough,
however. Over the past few years the explosion of methods
and instruments for assessing biological systemswith increasing
precision and breadth, in concert with the genetic resources
provided by the Human Genome Project and it successors,
has opened the door to an entirely new way to characterize
and explore human immunity. The old standby technology of446 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.flow cytometry has moved from considering a four-color exper-
iment as state of the art to routine use of nine to ten parameters
and the potential for near routine use of up to 15 or more
measurements to provide insight into not just cell phenotype
and subset identity (Chattopadhyay et al., 2008), but state of
activation, intracellular signaling status (through phosphoflow
[Schulz et al., 2007]), and effector activity. Indeed, novel instru-
mentation with mass spectrometry to detect isotopic rather
than fluorescent labels promises to increase the N-dimension-
ality of ‘‘flow’’ studies to >50 parameters in the next year or
two (Bandura et al., 2009). Multiplexed cytokine assays allow
nearly the entire known universe of such mediators to be
measured at one time with high precision and great sensitivity
in serum, sweat, other bodily fluids, or cellular supernatants.
Microarray technology and next-generation sequencing have
opened the door to obtaining complete determinations of the
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Perspectivetranscriptional state (and miRNA status) of immune cells in
human samples, most often blood, but because of the great
sensitivity of thesemethods, even the few cells present in biopsy
material. The combination of flow separation and these array
or sequencing methods will allow a finely resolved analysis of
transcripts in specific cell types, helping to make construction
of gene regulatory networks from such data more practical
and greatly enhancing the resolving power of the method with
respect to distinguishing normal from perturbed states when
these may only involve a minor hematological subset. Mass
spectrometry is making rapid advances in precision and cover-
age and can be applied to both qualitative and quantitative
tasks, including protein identification and cataloguing, post-
translational modification discovery, and metabolic studies
(Anderson et al., 2009; Choudhary and Mann, 2010; Gstaiger
and Aebersold, 2009; Schiess et al., 2009). These tools can be
combined with other rapidly emerging methods for analysis of
antigen-specific cells using multiplex tetramer technology
(Hadrup et al., 2009; Newell et al., 2009), for repertoire analysis
using advanced sequencing tools (Freeman et al., 2009), for
complete analysis of the genome and epigenome, for assess-
ment of microbiome diversity (Grice et al., 2009; Hamady and
Knight, 2009), and with new imaging methods for localizing
immune cells or their products within tissues, to develop
a remarkably deep and broad picture of the ‘‘normal’’ immune
status in an individual and to assess the changes induced by
infection, cancer, autoimmunity, inflammatory diseases, and,
of course, vaccination.
This ability to collect massive amounts of data because of this
growing capacity to interrogate the system with unbiased global
methods that do not require specific hypotheses but instead are
‘‘hypothesis generating’’ necessitates a major change in how
such data are handled. Rather than using biological intuition or
simple graphs, charts, and textbook statistical analyses, it will
be necessary to apply a sophisticated raft of informatics tools
to extract the greatest insight from these large data sets. Indeed,
experts in the emerging fields of bioinformatics and computa-
tional systems biomedicine are needed not only to help guide
post hoc interpretation of results but also to help plan the nature
and extent of the data gathered in the first place, to ensure that
it will be possible to draw reliable and significant conclusions
from the time, effort, and expense such extensive studies entail.
We are already beginning to see the value and power of applying
such computational approaches to systematically collected,
large-scale transcriptional data sets in assessing human immune
status (Chaussabel et al., 2008; Gaucher et al., 2008; Querec
et al., 2009), and methods for using multiple data types to
construct computationally useful models of organism-level
physiology are emerging (Sieberts and Schadt, 2007). A detailed
and insightful description of how such systems approaches,
especially those based on RNA expression profiling, can be
used to uncover the factors that control the nature and extent
of human immune responses to vaccines is presented in the
review by Pulendran et al. (2010).
Making a more than incremental advance in human immu-
nology will also require changing the usual way the field does
business in a sociological sense. A much greater degree of
cooperation and integration among laboratory and clinical inves-
tigators across diverse subspecialties will be needed and enter-prises capable of large-scale data collection with a high degree
of reliability and quality will be essential, as will the integration
into these efforts of computational experts that operate in a fully
coordinated manner with the physicians and biologists, rather
than being consulted after the fact. A new attitude toward
rapid data dissemination and sharing akin to the procedures fol-
lowed by the Human Genome Project (http://www.genome.gov/
12513440#al-1) will play a big role in moving the field forward at
themost rapid rate and producing the fastest translation of these
new data into clinical benefits for patients. Some of these
concepts and practices have already been put in place by the
large ongoing efforts of the Immune Tolerance Network (http://
www.immunetolerance.org/), but additional transparency in
data access, among other improvements, will make this and
other such efforts even more valuable to the entire research
community. The rapid data release and public access polices
of the ImmGen project for deep molecular phenotyping of
immune cells (http://www.immgen.org/index_content.html) is
another emerging example of how extensive consorted efforts
can provide major benefits to the entire field, not just the few
investigators actually funded for and involved in the data gath-
ering, and one hopes that the ImmGen program will rapidly
move from mouse to human cells in its analyses. Discussions
are underway among the centers planning or in the early stages
of efforts to conduct systems-level analysis of the human
immune system to share SOPs, make data sets as compatible
and as comparable as possible, draft data release guidelines,
share technology developments, and aggregate findings to allow
large meta-analyses that will be especially valuable in linking
genetic variation to immune behavior, whether with respect to
vaccine efficacy, autoimmune disease propensities, or thera-
peutic responses. An initial goal of the NIH CHI and most other
centers involved in this new approach to the study of human
immune function is to provide an in-depth description of the
normal human ‘‘immunome,’’ which will provide the entire com-
munity of investigators a reference point for assessment of the
disturbed state of the system in diseased individuals and for
relating the perturbations induced by various therapeutic inter-
ventions (including vaccines) to overall system function.
Concluding Remarks
Somewill be uneasy at best and dismissive at worst with respect
to the emphasis placed here on the promise of new ‘‘big
science’’ efforts in the field of human immunology. A key point
to be made is that the global, extensively multiplexed, omic-
scale analysis of the human immune system that underlies the
approach just discussed complements but in no way replaces
insightful, focused studies of the components and fine-grained
behavior of the immune system. The systems approach is not
designed to reveal the details of intracellular signaling pathways
in specific cells, although some of its technologies, like multiplex
phosphoflow, can contribute to such studies. It is not optimally
set up to discover a new type of cell if such a cell is only revealed
by a new surface marker to which an antibody is not available
and thus not included in the complex staining panels used for
flow analysis, although improved computational methods for
identifying cell subpopulations with unique combinations of
staining achieved with large numbers of known markers can
potentially identify such a cell type without the new antibody.Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 447
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two cell types communicate with one another, identifying the
counterligand of a novel immune receptor, or providing high-
resolution descriptions of either the positioning of various inflam-
matory cells in specific tissue sites or the pathology of the
involved tissue, although imaging methods may permit such
studies in the future as part of the large panel of assays done
in a systems-level enterprise.
The essential point is that ‘‘systems analysis’’ is really the new
‘‘physiology.’’ There is a renewed interest in understanding the
integrated functioning of the immune system in humans and
not just obtaining descriptions of a few of the parts and their indi-
vidual roles or nearest neighbor interactions, as important as
such knowledge is. There is a desire to use deep, extensive,
and quantitative measurements of as many aspects of the
integrated system as possible in a concerted effort to discern
the origins of disease and to provide insights into how to manip-
ulate the system for improved human health, including through
effective vaccination (Germain, 2001). Optimal use and interpre-
tation of such global studies require the specific knowledge
derived from conventional investigations as fundamental build-
ing blocks, and the detailed studies require systems-level efforts
to put the focused information they produce into a broader
context that provides a deeper mechanistic understanding of
how the various parts of the system work together to provide
protection in health or fail to do so in disease. Proponents of
this strategy certainly do not wish to overpromise, an issue dis-
cussed in some detail in Pulendran et al. (2010). Nonetheless,
it seems that only with such a more complete and integrated
understanding of immune function can we hope to develop
drugs and vaccines that work the way we want with limited
toxicity and do so in the most efficient manner. The reviews in
this issue provide insightful snapshots of the state of the art for
many specific aspects of immunity, host-pathogen interaction,
and vaccine development—the hope for the future is that such
knowledge will be blended together with the large-scale efforts
and systems approaches that are the heart of this Perspective
so that the next time the subject is reviewed in these pages,
a more holistic understanding of human immune function will
be evident and substantial progress to a new generation of effec-
tive vaccines will have been made based on this new insight.ACKNOWLEDGMENTS
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